OBJECTIVE: Evaluate aberrant drug-related behaviors in patients administering fentanyl buccal tablet or traditional short-acting opioids for breakthrough pain. DESIGN: Twelve-week open-label extension. SETTING: Forty-two US sites. SUBJECTS:Opioid-tolerantpatients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain. METHODS: Patients were rerandomized to continue treatment with fentanyl buccal tablet or begin any traditional short-acting opioid. Assessments included Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) at baseline and Addiction Behaviors Checklist and Current Opioid Misuse Measure at baseline and final visit. Case report forms were reviewed retrospectively to identify aberrant drug-related behaviors. RESULTS:One hundred thirty patients entered the open-label extension (fentanyl buccal tablet, N = 65; traditional short-acting opioid, N = 65). SOAPP-R scores were <18 (low risk of aberrant drug-related behavior) in 74% of patients; no significant differences in SOAPP-R scores were observed between treatment groups. At the final visit, ≤14% of patients in each treatment group had scores indicating potential aberrant drug-related behavior (Addiction Behaviors Checklist ≥3, Current Opioid Misuse Measure ≥9); no significant differences in scores were observed between treatment groups. Baseline SOAPP-R score ≥18 was not predictive of Addiction Behaviors Checklist ≥3 but was predictive of Current Opioid Misuse Measure ≥9. Aberrant behaviors were identified in 12 (18%) fentanyl buccal tablet patients and 13 (20%) traditional short-acting opioid patients. CONCLUSIONS:Incidence of aberrant drug-related behaviors was similar between patients taking fentanyl buccal tablet and traditional short-acting opioids over 12 weeks. Wiley Periodicals, Inc.
RCT Entities:
OBJECTIVE: Evaluate aberrant drug-related behaviors in patients administering fentanyl buccal tablet or traditional short-acting opioids for breakthrough pain. DESIGN: Twelve-week open-label extension. SETTING: Forty-two US sites. SUBJECTS: Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain. METHODS:Patients were rerandomized to continue treatment with fentanyl buccal tablet or begin any traditional short-acting opioid. Assessments included Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) at baseline and Addiction Behaviors Checklist and Current Opioid Misuse Measure at baseline and final visit. Case report forms were reviewed retrospectively to identify aberrant drug-related behaviors. RESULTS: One hundred thirty patients entered the open-label extension (fentanyl buccal tablet, N = 65; traditional short-acting opioid, N = 65). SOAPP-R scores were <18 (low risk of aberrant drug-related behavior) in 74% of patients; no significant differences in SOAPP-R scores were observed between treatment groups. At the final visit, ≤14% of patients in each treatment group had scores indicating potential aberrant drug-related behavior (Addiction Behaviors Checklist ≥3, Current Opioid Misuse Measure ≥9); no significant differences in scores were observed between treatment groups. Baseline SOAPP-R score ≥18 was not predictive of Addiction Behaviors Checklist ≥3 but was predictive of Current Opioid Misuse Measure ≥9. Aberrant behaviors were identified in 12 (18%) fentanyl buccal tablet patients and 13 (20%) traditional short-acting opioid patients. CONCLUSIONS: Incidence of aberrant drug-related behaviors was similar between patients taking fentanyl buccal tablet and traditional short-acting opioids over 12 weeks. Wiley Periodicals, Inc.
Authors: Jennifer Harman Ehrentraut; Kathleen Danielle Kern; Sarah A Long; Angel Qi An; Lane G Faughnan; Doralina L Anghelescu Journal: J Pediatr Psychol Date: 2014-09-14
Authors: Stephen Bruehl; John W Burns; Steven D Passik; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; Erik Schuster; Daria Orlowska; Christopher R France Journal: J Pain Date: 2015-04-16 Impact factor: 5.820
Authors: Mia Schmidt-Hansen; Michael I Bennett; Stephanie Arnold; Nathan Bromham; Jennifer S Hilgart; Andrew J Page; Yuan Chi Journal: Cochrane Database Syst Rev Date: 2022-06-09
Authors: Mia Schmidt-Hansen; Michael I Bennett; Stephanie Arnold; Nathan Bromham; Jennifer S Hilgart Journal: Cochrane Database Syst Rev Date: 2017-08-22
Authors: Valentina Nikulina; Honoria Guarino; Michelle C Acosta; Lisa A Marsch; Cassandra Syckes; Sarah K Moore; Russell K Portenoy; Ricardo A Cruciani; Dennis C Turk; Andrew Rosenblum Journal: Pain Date: 2016-08 Impact factor: 7.926
Authors: D Andrew Tompkins; Patrick S Johnson; Michael T Smith; Eric C Strain; Robert R Edwards; Matthew W Johnson Journal: Pain Date: 2016-08 Impact factor: 7.926
Authors: Jennifer M Hah; Yasamin Sharifzadeh; Bing M Wang; Matthew J Gillespie; Stuart B Goodman; Sean C Mackey; Ian R Carroll Journal: Pain Res Treat Date: 2015-12-31